|
31
|
Product specific BE guideline |
Lidocaine Patch-學名藥生體相等性試驗指導原則
|
2022-12-28 |
|
32
|
Product specific BE guideline |
Drospirenone/Ethinyl Estradiol Tablets-學名藥生體相等性試驗指導原則
|
2022-12-28 |
|
33
|
Product specific BE guideline |
Sorafenib Tosylate Tablets-學名藥生體相等性試驗指導原則
|
2022-12-28 |
|
34
|
Product specific BE guideline |
Sunitinib Hard Capsules-學名藥生體相等性試驗指導原則
|
2022-12-28 |
|
35
|
Product specific BE guideline |
Temozolomide Capsules-學名藥生體相等性試驗指導原則
|
2022-12-28 |
|
36
|
Product specific BE guideline |
Ticagrelor Tablets-學名藥生體相等性試驗指導原則
|
2022-12-28 |
|
37
|
Product specific BE guideline |
Trientine Dihydrochloride Capsules-學名藥生體相等性試驗指導原則
|
2022-12-28 |
|
38
|
Product specific BE guideline |
Rivaroxaban Tablets-學名藥生體相等性試驗指導原則
|
2022-12-28 |
|
39
|
Product specific BE guideline |
Tadalafil Tablets-學名藥生體相等性試驗指導原則
|
2022-12-28 |
|
40
|
Clinical |
抗癌藥品臨床評估考量重點指導原則(第二版)
|
2022-12-15 |
